linjc16/ctgov huggingface dataset:
Treatment of Epiretinal Membranes With Ranibizumab

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.

Official Title
-----------------
A Prospective Pilot Study of Lucentis for Epiretinal Membranes: the LERM Study

Conditions
-----------------
Epiretinal Membrane

Intervention / Treatment
-----------------
* Drug: intravitreal ranibizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: symptomatic idiopathic epiretinal membrane Exclusion Criteria: vision worse than 6/18 and fit for surgery prior vitreoretinal surgery or injection diabetes any past or current form of retinal vein occlusion or neovascularization age-related macular degeneration other condition causing significant limitation of visual potential

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ranibizumab<br>('intravitreal ranibizumab' ) | Drug: intravitreal ranibizumab<br>* monthly injections x3 +/- 2nd series of 3<br>* Other names: Lucentis;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evidence of improvement measured by optical coherence tomography |  | 3 and 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distance visual acuity (ETDRS) |  | 3 and 6 months | 
| Near visual acuity (Snellen) |  | 3 and 6 months | 
| Subjective change in symptoms |  | 3 and 6 months | 
| Amsler grid improvement |  | 3 and 6 months | 
| Quality of life improvement |  | 6 months |
Diagnostic Values of C-reactive Protein and Procalcitonin in Predicting Bacterial Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Study Overview
=================
Brief Summary
-----------------
Chronic obstructive pulmonary disease is a serious disease . Exacerbations of Chronic obstructive pulmonary disease is an acute worsening condition of Chronic obstructive pulmonary disease, which always accompanied by clinical symptoms such as, shortness of breath and increased production of sputum. Respiratory infection (bacteria or viruses or mixed) is thought to be the main cause in most exacerbations.

Official Title
-----------------
Diagnostic Values of C-reactive Protein and Procalcitonin in Predicting Bacterial Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Diagnostic Test: C- reactive protein
* Diagnostic Test: Pro calcitonin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients admitted to the hospital Exclusion Criteria: patients with malignancies patients with other systemic infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chronic obstructive pulmonary disease<br>patients with acutely exacerbated Chronic obstructive pulmonary disease admitted in chest department Assiut university hospital ,30 patients who revealed sputum culture and inflammatory markers suggesting infection exacerbation will be followed up | Diagnostic Test: C- reactive protein<br>* the measurement will be done by chemileumeniscence<br>Diagnostic Test: Pro calcitonin<br>* the measurement will be done by chemileumeniscence<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The level of C-reactive protein between Infection and Non-infectious inflammatory response in acute exacerbations of Chronic obstructive pulmonary disease patients | Patients will be classified into cases with Infection or non-infectious inflammatory response according to the level of C-reactive protein | 24 hours |
Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin

Study Overview
=================
Brief Summary
-----------------
Hepatorenal syndrome is a common complication of cirrhotic patients. The prognosis of patients with HRS is very poor. It have been demonstrated that vasoconstrictors agents (Terlipressin) plus albumin are effective in the reversal of the treatment. However, previous studies are pilot studies and they are not able to give information about an improvement in survival. This comparative randomized study was delineated to test the efficacy of terlipressin on survival.

Detailed Description
-----------------
Phase 3

Official Title
-----------------
Terlipressin as Treatment of Patients With Cirrhosis and Hepatorenal Syndrome. Effect on Survival and Renal Function. Multicenter, Randomized and Prospective Study

Conditions
-----------------
Cirrhosis, Hepatorenal Syndrome

Intervention / Treatment
-----------------
* Drug: terlipressin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with HRS type 1 or 2 with serum creatinine >2 mg/dL Age between 18 and 75 years Written informed consent. Absence of exclusion criteria Exclusion Criteria: Hepatocarcinoma (3 nodules greater than 3 cm or 1 nodule > than 5 cm) Active infection with systemic inflammatory response syndrome Respiratory or cardiac dysfunction. Arteriopathy. Ischemic cardiopathy. Arterial hypertension ( >140/90 mmHg during hospitalization )

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: terlipressin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hepatorenal syndrome, terlipressin, albumin, cirrhosis
Proton Pump Inhibitors and Dysbiosis in Cirrhosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to find out whether the use of medications that suppress acid in your stomach can change the composition of your bowel bacteria.

Conditions
-----------------
Cirrhosis, Healthy

Intervention / Treatment
-----------------
* Drug: Omeprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for PPI initiation study: Cirrhosis not on current PPI or acid suppressive therapy No systemic antibiotics or probiotics Exclusion Criteria for PPI initiation study: On systemic antibiotics On PPI or acid suppression therapy already unable to give informed consent Allergy to proton pump inhibitors Inclusion Criteria for PPI withdrawal study: Cirrhosis on current PPI for an FDA-unapproved indication No systemic antibiotics or probiotics Exclusion Criteria for PPI withdrawal study: On systemic absorbable antibiotics On PPI or acid suppression therapy for an FDA-approved indication unable to give informed consent unwilling to withdraw PPI

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Interventional Model Description: PPI withdrawal (decompensated patients only) and PPI initiation (compensated and decompensated patients)
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PPI inititation<br>Adding 40mg omeprazole QD for 14 days | Drug: Omeprazole<br>* 20mg PO BID for 20 days<br>|
| Active Comparator: PPI withdrawal<br>The intervention here is systematically withdrawing chronic PPI for 14 days | Drug: Omeprazole<br>* 20mg PO BID for 20 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Patients With Overgrowth of Oral Microbiota in Their Stool After PPI Therapy Withdrawal or Initiation | Analysis at baseline will be compared to that at 2 weeks using Multitagged sequencing. Number of patients with overgrowth of oral microbiota in their stool after PPI therapy withdrawal or initiation were specifically analyzed. | 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Patients With Adverse Events During Initiation or Withdrawal of PPI Therapy | Analysis at baseline will be compared to that at 2 weeks. This will be specifically, changes in those with PPI withdrawal compared to those with PPI initiation | 2 weeks |
Derris Scandens Benth Extract VS Naproxen in Knee OA

Study Overview
=================
Brief Summary
-----------------
Derris Scandens Benth (family : Leguminosae) is a woody vine growing throughout Southeast Asia, including Thailand. The stem of D.Scandens has been widely use in Thai traditional medicine, foe example of myalgia. Previous study shown that D.Scandens Benth extract has the anti-inflammatory activity. Although NSAIDs are efficaciously in the treatment of osteoarthritis,but the GI side effect is still concerned. In this study we aim to investigate the efficacy and safety of D. Scandens Benth extract compared with Naproxen for therapy of patients with knee osteoarthritis.

Official Title
-----------------
The Efficacy and Safety of Derris Scandens Benth Extract and Naproxen for Therapy of Patients With Knee Osteoarthritis

Conditions
-----------------
Knee Osteoarthritis

Intervention / Treatment
-----------------
* Drug: Derris scandens Benth extracts
* Drug: naproxen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >=50 yr Known case of primary knee osteoarthritis WOMAC pain subscale (item1) >= 5 signed informed consent Exclusion Criteria: hypersensitive to NSAIDs history of peptic ulcer or melena unable to walk , i.e. patient with severe spinal stenosis, myocardial infarction history of intra-articular injection of knee within 3 months status post knee replacement

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: naproxen<br>Naproxen 500 mg/day for 4 weeks | Drug: naproxen<br>* Naproxen 500 mg/day for 4 weeks<br>|
| Experimental: Derris Scandens Benth<br>Derris Scandens Benth | Drug: Derris scandens Benth extracts<br>* Derris scandens Benth extracts (oral) 400 mg twice per day for 4 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| WOMAC score |  | 2, 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 6-minute walk, Quality of Life, adverse event |  | 2, 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Derris Scandens Benth extract, Osteoarthritis, WOMAC, 6-minute walk
Study to Assess the Safety and Patients' Satisfaction of Tears Again* in the Treatment of Dry Eye Symptoms

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine safety and patients' satisfaction when using Tears Again to treat Dry Eye Symptoms.

Official Title
-----------------
An Open Study to Assess the Safety and Patients' Satisfaction Tears Again* in the Treatment of Dry Eye Symptoms

Conditions
-----------------
Dry Eye Syndrome

Intervention / Treatment
-----------------
* Drug: Tears Again


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suffer from at least two of the following ocular symptoms: burning, stinging, excessive tearing, dryness, grittiness, foreign body sensation ( including patients suffering from blepharitis). Use artificial tears or any other treatment for these symptoms three or more times a day. Exclusion Criteria: Known hypersensitivity to Phenoxyethanol. Pregnant and lactating women. Receive other ophthalmic medication (except for eyelid hygiene preparations). Graft-versus-host disease patients. Participated during the last month in another clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tears Again<br>All subjects shall be treated with Tears Again. | Drug: Tears Again<br>* Liposome Eye Spray<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Schirmer Test, Lissamine Green Test and BUT. |  | On enrollment and one month later. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Questionaire |  | One, three and four weeks after treatment commencement. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dry Eye Syndrome
Postspinal Headache and Near Infrared Spectroscopy (NIRS)

Study Overview
=================
Brief Summary
-----------------
Evaluation of the relationship between postspinal headache and near infrared spectroscopy in cesarean section patients

Detailed Description
-----------------
Patients with cesarean section under spinal anesthesia were included in the study. Before the study, patients were moniterized with NIRS device in the preoperative waiting room.NIRS moniterization was continued intraoperatively at 1st, 4th, 7th, 10th, 15th, 30th minutes and 24th postoperative period. Patients were divided into two groups as those with postspinal headache (Group A) and those with postspinal headache (Group B). In this study, NIRS values between two groups were compared.

Official Title
-----------------
Evaluation of the Relationship Between Postspinal Headache and Near Infrared Spectroscopy in Cesarean Section Patients

Conditions
-----------------
Tissue Oxygenation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective cesarean section Exclusion Criteria: Not willing to participate in the study Use of anti-psychotic or anti-depressant drugs Patients with headaches

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Near Infrared spectroscopy | Tissue oxygenation | Up to 20 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cesarean section, post spinal headache, Near Infrared spectroscopy
Comparison of Cardiac Output Measured by Ultrasound Dilution Method and Pulmonary Artery Thermodilution Technique

Study Overview
=================
Brief Summary
-----------------
Cardiac output (CO) is an important hemodynamic variable in the management of critically ill patients. The pulmonary artery catheter (PAC) requires invasive techniques with potential complications and there is increasing interest in less invasive methods of measuring CO. This study is designed to compare CO values from PAC thermodilution (COTD) and ultrasound dilution (COUD).

Official Title
-----------------
Comparison of Cardiac Output Measured by Ultrasound Dilution Method and Pulmonary Artery Thermodilution Technique

Conditions
-----------------
Cardiac Disease, Post Surgery Patients

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years of age Presence of arterial catheter plus central venous pressure monitor and pulmonary artery catheter for hemodynamic monitoring. Exclusion Criteria: Age < 18 years of age Patients with structurally abnormal heart (e.g. shunt) (confirmed by history taking) Patients who have heparin allergy. (Confirmed by history taking)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare Cardiac Output Measurements | To compare CO measured by ultrasound dilution method (COUD) and pulmonary artery thermodilution technique (COTD) in SICU (Surgical Intensive Care Unit) patients. | During the stay in the ICU with in situ catheters (expected avg 3 days) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiac output, ultrasound dilution, thermodilution
Cardiovascular Impact of Obstructive Sleep Apnea Treatment in Normotensive Patients

Study Overview
=================
Brief Summary
-----------------
Recent evidences suggest that obstructive sleep apnea (OSA) can contribute to cardiovascular disease even in the absence of hypertension. However, there are few data regarding the impact of OSA on the preHypertension and Masked Hypertension in apparently normotensive patients with OSA as well as the impact of treatment with continuous positive airway pressure.

Official Title
-----------------
Cardiovascular Impact of Obstructive Sleep Apnea in Normotensive Patients and the Effects of Continuous Positive Airway Pressure

Conditions
-----------------
Obstructive Sleep Apnea

Intervention / Treatment
-----------------
* Device: CPAP
* Device: CPAP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Severe OSA patients Exclusion Criteria: Smoking Sustained Hypertension Heart failure Diabetes Renal diseases Under use of any medication Under treatment for OSA

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 1<br>Control group | Device: CPAP<br>* Control - no treatment<br>|
| Active Comparator: 2<br>CPAP | Device: CPAP<br>* CPAP: The airway pressure will be determined by an overnight sleep study titration.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Office Blood Pressure | Evaluation of PreHypertension |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 24 Hour Ambulatory Blood Pressure Monitoring | Evaluation of Masked Hypertension |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obstructive Sleep Apnea, Blood Pressure, PreHypertension, Masked Hypertension
REINFORCEMENT ANASTOMOSIS WITH Modified Cyanacrylate IN Patients Undergoing to Oncologic Colorectal Surgery With Colorectal Anastomosis

Study Overview
=================
Brief Summary
-----------------
In colorectal surgery about 30% of postoperative mortality is attributed to anastomotic leak, whit an incidence range between 1.8% and 15.9%. Preventing the anastomotic leak can therefore bring benefits to the patient and the health system. To date we have technologically advanced suturizers and the correct realization (well-vascularized margins, not in tension, etc.) remains crucial to prevent anastomotic dehiscence. Experimental results demonstrate that modified cyanacrylate is a suitable potential reinforcement on intestinal anastomoses (manual or linear intra-corporeal). Applied after mechanical anastomosis, it polymerizes in a short time, closing the spaces of the suture line between one point and the other, expressing an adhesive, hemostatic and sealing action on the tissues, also creating an effective antiseptic barrier towards of the most common infectious or pathogenic agents.

Official Title
-----------------
REINFORCEMENT ANASTOMOSIS IN ONCOLOGIC COLORECTAL SURGERY

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Device: colectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent patients undergoing to oncologic colorectal surgery with colorectal anastomosis Exclusion Criteria: refuse informed consent patients undergoing to oncologic colorectal surgery without colorectal anastomosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: colectomy|colectomy resection|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fistula incidence |  | From day of surgery up to 30 postoperative days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| anastomitic bleeding |  | From day of surgery up to 30 postoperative days | 
| infection |  | From day of surgery up to 30 postoperative days |